Composition :
Each gram contains Clindamycin phosphate equivalent
to clindamycin ................................................................. 10 mg
Pharmacology:
Rapid in vivo hydrolysis converts Clindamycin phosphate to the antibacterially active clindamycin. Clindamycin in vitro inhibits all Propionibacterium acnes cultures tested. Free fatty acids on the skin surface have been decreased from approximately 14% to 2% following application of clindamycin.
Indications:
CLINIKA Lotion is indicated in the treatment of acne vulgaris.
Dosage and Administration:
Apply a thin film of CLINIKA Lotion twice daily to affected area. Shake well before using.
Warnings and Precautions:
· Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. As with orally administered clindamycin when diarrhea occurs, the drug should be discontinued.
· CLINIKA should be prescribed with caution in atopic individuals.
· This drug should be used for pregnant women or nursing mothers only if clearly needed.
· Safety and effectiveness is pediatric patients under the age of 12 have not been established.
Adverse reactions :
Burning, itching, skin dryness, erythema, skin oiliness, peeling, dermatologic irritation, gram-negative folliculitis, gastrointestinal disturbances and abdominal pain.
Drug Interactions:
· Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore it should be used with caution in patients receiving such agents.
· Antagonism has been demonstrated between clindamycin and erythromycin in vitro . Because of possible clinical significance, these two drugs should not be administered concurrently.
Container 10 g Reg. No.: DKL 0409318028A1 |
